Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
SELLAS Life Sciences Group, Inc. (SLS)
USD12.62
-0.14 (-1.10%)
US NASDAQ Healthcare Biotechnology
Address
7 Times Square 10036
New York, NY, US
New York, NY, US
CEO
Angelos Stergiou
Website
sellaslifesciences.com
IPO
2008-03-12
CIK 1390478 ISIN US81642T2096
Description
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
News Sentiment (7d)
Based on only 1 article — low confidence
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD12.62
-0.14 (-1.10%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
8M
Beta
2.53
Float Shares
140.17M
Free Float %
98.4%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +25.10% | +31.92% | +37.18% | +81.89% | +347.26% | +73.21% | +363.12% | +298.17% | -14.19% | -99.98% | -100.00% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (5 ratings, all time)
Buy
Price Targets & DCF
Current price
12.62
Low
2.40
-81.0%
Consensus
2.80
-77.8%
Median
2.80
-77.8%
High
3.20
-74.6%
DCF (Unlevered)
0.63
-95.0%
DCF (Levered)
0.65
-94.8%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 1 | -1 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | — | — |
| All Time | 2 |
2.80
-77.8%
|
Quality scores
Altman Z-Score
62.68
Safe zone
Piotroski F-Score
2 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+50.0% ★ Q1'26: +24.5% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: -3,407.7% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+78.2% Q1'26: +96.5% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.04× Q1'26: -0.02× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 2 EPS Ana. |
Dec 2028 1 Rev. Ana. 2 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
—
est: 8.29M (-100.0%)
|
7.60M
est: 5.07M (+50.0%)
|
1.00M
est: 1.00M (+0.0%)
|
—
est: 13.00M (-100.0%)
|
—
|
—
est: 31.98M (-100.0%)
|
36.13M
36.13M – 36.13M
+13.0% YoY
|
44.25M
44.25M – 44.25M
+22.4% YoY
|
101.70M
101.70M – 101.70M
+129.9% YoY
|
321.38M
321.38M – 321.38M
+216.0% YoY
|
575.93M
575.93M – 575.93M
+79.2% YoY
|
| EBITDA |
-37.48M
est: -1.66M (-2,160.6%)
|
-18.32M
est: -1.01M (-1,708.0%)
|
-31.49M
est: -200.0K (-15,646.6%)
|
529.0K
est: -2.60M (+120.3%)
|
632.0K
|
-28.27M
est: 6.40M (-542.0%)
|
7.23M
7.23M – 7.23M
+13.0% YoY
|
8.85M
8.85M – 8.85M
+22.4% YoY
|
20.34M
20.34M – 20.34M
+129.9% YoY
|
64.28M
64.28M – 64.28M
+216.0% YoY
|
115.19M
115.19M – 115.19M
+79.2% YoY
|
| EBIT |
-37.83M
est: -1.66M (-2,182.1%)
|
-19.59M
est: -1.01M (-1,833.6%)
|
-31.95M
est: -200.0K (-15,875.1%)
|
-37.34M
est: -2.60M (-1,336.2%)
|
-30.88M
|
-28.27M
est: 6.40M (-542.0%)
|
7.23M
7.23M – 7.23M
+13.0% YoY
|
8.85M
8.85M – 8.85M
+22.4% YoY
|
20.34M
20.34M – 20.34M
+129.9% YoY
|
64.28M
64.28M – 64.28M
+216.0% YoY
|
115.19M
115.19M – 115.19M
+79.2% YoY
|
| Net Income |
-63.90M
est: -5.47T (+100.0%)
|
-20.70M
est: -818.58M (+97.5%)
|
-41.30M
est: -1.28B (+96.8%)
|
-37.34M
est: -616.11M (+93.9%)
|
-30.88M
est: -32.85M (+6.0%)
|
-26.86M
est: -28.35M (+5.3%)
|
-30.53M
-30.53M – -30.53M
-7.7% YoY
|
-26.70M
-27.26M – -7.63M
+12.6% YoY
|
-7.51M
-27.26M – 32.72M
+71.9% YoY
|
201.74M
201.74M – 201.74M
+2,786.0% YoY
|
398.04M
398.04M – 398.04M
+97.3% YoY
|
| SGA |
10.25M
est: 35.02M (-70.7%)
|
11.32M
est: 21.41M (-47.1%)
|
12.58M
est: 4.22M (+197.8%)
|
13.86M
est: 54.92M (-74.8%)
|
12.42M
|
12.25M
est: 109.19M (-88.8%)
|
123.37M
123.37M – 123.37M
+13.0% YoY
|
151.07M
151.07M – 151.07M
+22.4% YoY
|
347.24M
347.24M – 347.24M
+129.9% YoY
|
1.10B
1.10B – 1.10B
+216.0% YoY
|
1.97B
1.97B – 1.97B
+79.2% YoY
|
| EPS |
-411.55
est: -8,940.00 (+95.4%)
|
-1.34
est: -1.34 (-0.2%)
|
-2.13
est: -2.10 (-1.5%)
|
-1.34
est: -1.01 (-33.1%)
|
-0.50
est: -0.54 (+6.8%)
|
-0.25
est: -0.26 (+3.8%)
|
-0.28
-0.28 – -0.28
-7.7% YoY
|
-0.16
-0.25 – -0.07
+42.9% YoY
|
0.03
-0.25 – 0.30
+115.6% YoY
|
1.85
1.85 – 1.85
+7,300.0% YoY
|
3.65
3.65 – 3.65
+97.3% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-01 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-24 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-23 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-15 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-28.39M
OE per share TTM
-0.28
Owner's Yield
-3.53%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
52.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
63
Total invested
22.78M
Insider transactions (90d)
0
Beneficial owners (>5%)
29
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 13G | 5.00M | 9.70% | — | 5.00M | — | 5.00M | IN | Texas | 2019-06-24 | ↗ |
| 2 | Empery Asset Management, LP | 3.80M | 4.99% | — | 3.80M | — | — | PN | Delaware | 2019-01-17 | ↗ |
| 3 | Martin D. Hoe | 3.80M | 4.99% | — | 3.80M | — | — | IN | United States | 2019-01-17 | ↗ |
| 4 | Ryan M. Lane | 3.80M | 4.99% | — | 3.80M | — | — | IN | United States | 2019-01-17 | ↗ |
| 5 | Altium Growth GP, LLC | 2.80M | 9.81% | — | 2.80M | — | — | PN | Delaware, United States of America | 2018-07-23 | ↗ |
| 6 | Highbridge Capital Management, LLC | 2.08M | 6.50% | — | 2.08M | — | — | IA, OO | State of Delaware | 2024-02-07 | ↗ |
| 7 | Empery Tax Efficient II, LP | 1.98M | 4.99% | — | 1.98M | — | — | PN | Delaware | 2019-01-17 | ↗ |
| 8 | Empery Asset Master, Ltd. | 1.40M | 4.99% | — | 1.40M | — | — | PN | Cayman Islands | 2019-01-17 | ↗ |
| 9 | Globis Capital Advisors, L.L.C. | 497.4K | 5.30% | — | 497.4K | — | 497.4K | OO | Delaware | 2020-09-21 | ↗ |
| 10 | Globis Capital Management, L.P. | 497.4K | 5.30% | — | 497.4K | — | 497.4K | PN | Delaware | 2020-09-21 | ↗ |
| 11 | Globis Capital Partners, L.P. | 497.4K | 5.30% | — | 497.4K | — | 497.4K | PN | Delaware | 2020-09-21 | ↗ |
| 12 | Globis Capital, L.L.C. | 497.4K | 5.30% | — | 497.4K | — | 497.4K | OO | Delaware | 2020-09-21 | ↗ |
| 13 | s: Paul Packer | 497.4K | 5.30% | — | 497.4K | — | 497.4K | IN | Delaware | 2020-09-21 | ↗ |
| 14 | CVI Investments, Inc. | 315.2K | 2.70% | — | 315.2K | — | 315.2K | CO | Cayman Islands | 2021-02-16 | ↗ |
| 15 | Heights Capital Management, Inc. | 315.2K | 2.70% | — | 315.2K | — | 315.2K | CO | Cayman Islands | 2021-02-16 | ↗ |
| 16 | (. | 190.0K | 1.50% | 190.0K | — | 190.0K | — | IN | United States | 2020-12-14 | ↗ |
| 17 | 27-4413262 | 190.0K | 1.50% | 190.0K | — | 190.0K | — | OO | Maryland | 2020-12-14 | ↗ |
| 18 | s: Globis Capital Partners, L.P. | 141.6K | 1.20% | — | 141.6K | — | 141.6K | PN | Delaware | 2021-02-12 | ↗ |
| 19 | Altium Capital Management, LP | 56.0K | 1.10% | — | 56.0K | — | — | IA | Delaware, United States of America | 2020-02-14 | ↗ |
| 20 | Altium Growth Fund, LP | 56.0K | 1.10% | — | 56.0K | — | — | PN | Delaware, United States of America | 2020-02-14 | ↗ |
| 21 | 683 Capital Management, LLC | 38.0K | 1.00% | — | 38.0K | — | 38.0K | IA | Delaware | 2020-02-13 | ↗ |
| 22 | 683 Capital Partners, LP | 38.0K | 1.00% | — | 38.0K | — | 38.0K | PN | Delaware | 2020-02-13 | ↗ |
| 23 | Ari Zweiman | 38.0K | 1.00% | — | 38.0K | — | 38.0K | IN | Delaware | 2020-02-13 | ↗ |
| 24 | Inc. | — | 0.00% | — | — | — | — | FI, CO | Ontario Canada | 2020-02-14 | ↗ |
| 25 | Kassam | — | 0.00% | — | — | — | — | HC, IN | Ontario Canada | 2020-02-14 | ↗ |
| 26 | LLC | — | 0.00% | — | — | — | — | HC, OO | Ontario Canada | 2020-02-14 | ↗ |
| 27 | Management LP | — | 0.00% | — | — | — | — | IA, PN | Ontario Canada | 2020-02-14 | ↗ |
| 28 | Nathoo | — | 0.00% | — | — | — | — | HC, IN | Ontario Canada | 2020-02-14 | ↗ |
| 29 | Winson | — | 0.00% | — | — | — | — | HC, IN | Ontario Canada | 2020-02-14 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
63
-65 vs prev Q
New positions
24
Closed positions
79
Increased
41
Reduced
6
Put/Call ratio
0.00
Calls held
15.5K
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 8.47M +1.6M (+23.8%) | 31.92M +20.9M (+189.9%) | 7.81% +0.872 pp | 0.00% +0.000 pp | USD2.61 +44.4% | 25 qtrs — |
| 2 | BLACKROCK, INC. | 7.54M +1.9M (+32.6%) | 28.43M +19.3M (+210.5%) | 6.96% +1.187 pp | 0.00% +0.000 pp | USD2.42 +55.8% | 6 qtrs — |
| 3 | GEODE CAPITAL MANAGEMENT, LLC | 3.08M +813.0K (+35.9%) | 11.60M +8.0M (+218.2%) | 2.84% +0.541 pp | 0.00% +0.001 pp | USD2.63 +43.3% | 25 qtrs — |
| 4 | STATE STREET CORP | 2.19M +827.3K (+60.8%) | 8.25M +6.1M (+276.5%) | 2.02% +0.638 pp | 0.00% +0.000 pp | USD2.81 +34.2% | 19 qtrs — |
| 5 | MILLENNIUM MANAGEMENT LLC | 1.39M +1.1M (+341.0%) | 5.23M +4.7M (+932.7%) | 1.28% +0.961 pp | 0.00% +0.002 pp | USD3.41 +10.6% | 3 qtrs — |
| 6 | MARSHALL WACE, LLP | 1.34M -1.0M (-43.1%) | 5.05M +1.3M (+33.1%) | 1.24% -1.156 pp | 0.00% +0.001 pp | USD2.19 +72.1% | 4 qtrs — |
| 7 | TWO SIGMA INVESTMENTS, LP | 1.08M +936.4K (+642.0%) | 4.08M +3.8M (+1,637.4%) | 1.00% +0.850 pp | 0.01% +0.005 pp | USD3.52 +7.1% | 6 qtrs — |
| 8 | NUVEEN, LLC | 1.02M +26.1K (+2.6%) | 3.86M +2.3M (+140.3%) | 0.94% -0.068 pp | 0.00% +0.001 pp | USD2.22 +69.8% | 3 qtrs — |
| 9 | NORTHERN TRUST CORP | 930.8K +199.6K (+27.3%) | 3.51M +2.3M (+198.1%) | 0.86% +0.117 pp | 0.00% +0.000 pp | USD2.46 +53.3% | 21 qtrs — |
| 10 | MORGAN STANLEY | 890.9K -163.9K (-15.5%) | 3.36M +1.7M (+97.8%) | 0.82% -0.248 pp | 0.00% +0.000 pp | USD2.13 +77.0% | 25 qtrs — |
| 11 | SIG BROKERAGE, LP | 743.0K +743.0K (+100.0%) | 2.80M +2.8M (+100.0%) | 0.69% +0.685 pp | 0.09% +0.087 pp | USD3.77 +0.0% | 1 qtrs NEW |
| 12 | TUDOR INVESTMENT CORP ET AL | 685.7K +685.7K (+100.0%) | 2.59M +2.6M (+100.0%) | 0.63% +0.633 pp | 0.00% +0.005 pp | USD3.77 +0.0% | 1 qtrs NEW |
| 13 | DAGCO, INC. | 577.5K +577.5K (+100.0%) | 2.18M +2.2M (+100.0%) | 0.53% +0.533 pp | 0.50% +0.503 pp | USD3.77 +0.0% | 1 qtrs NEW |
| 14 | NOMURA HOLDINGS INC | 523.7K +523.7K (+100.0%) | 1.97M +2.0M (+100.0%) | 0.48% +0.483 pp | 0.00% +0.003 pp | USD3.77 +0.0% | 1 qtrs NEW |
| 15 | CLEAR STREET GROUP INC. | 500.0K +500.0K (+100.0%) | 1.89M +1.9M (+100.0%) | 0.46% +0.461 pp | 0.01% +0.007 pp | USD3.77 +0.0% | 1 qtrs NEW |
| 16 | EVERHART FINANCIAL GROUP, INC. | 466.2K +135.1K (+40.8%) | 1.76M +1.2M (+229.7%) | 0.43% +0.094 pp | 0.16% +0.109 pp | USD2.24 +68.3% | 2 qtrs — |
| 17 | JONES FINANCIAL COMPANIES LLLP | 429.2K +428.9K (+114,670.9%) | 1.62M +1.6M (+265,186.2%) | 0.40% +0.396 pp | 0.00% +0.001 pp | USD3.77 +0.0% | 7 qtrs — |
| 18 | DIADEMA PARTNERS LP | 424.9K +24.9K (+6.2%) | 1.60M +957.9K (+148.7%) | 0.39% -0.014 pp | 0.28% +0.111 pp | USD2.28 +65.4% | 3 qtrs — |
| 19 | GOLDMAN SACHS GROUP INC | 411.7K +392.4K (+2,036.8%) | 1.55M +1.5M (+4,903.5%) | 0.38% +0.360 pp | 0.00% +0.000 pp | USD3.70 +1.9% | 5 qtrs — |
| 20 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 408.4K +114.3K (+38.9%) | 1.54M +1.1M (+225.2%) | 0.38% +0.078 pp | 0.00% +0.000 pp | USD2.63 +43.3% | 14 qtrs — |
| 21 | GSA CAPITAL PARTNERS LLP | 345.1K -173.9K (-33.5%) | 1.30M +465.0K (+55.6%) | 0.32% -0.208 pp | 0.11% +0.042 pp | USD2.04 +84.8% | 4 qtrs — |
| 22 | OPUS CAPITAL GROUP, LLC | 317.1K +67.1K (+26.8%) | 1.20M +792.0K (+196.5%) | 0.29% +0.039 pp | 0.13% +0.084 pp | USD1.77 +113.0% | 13 qtrs — |
| 23 | WELLS FARGO & COMPANY/MN | 299.3K +223.4K (+294.5%) | 1.13M +1.0M (+823.8%) | 0.28% +0.199 pp | 0.00% +0.000 pp | USD3.32 +13.6% | 4 qtrs — |
| 24 | JANE STREET GROUP, LLC | 282.7K +156.5K (+124.0%) | 1.07M +862.6K (+424.5%) | 0.26% +0.133 pp | 0.00% +0.000 pp | USD2.76 +36.6% | 6 qtrs — |
| 25 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 276.7K +216.4K (+358.9%) | 1.04M +946.1K (+974.5%) | 0.26% +0.194 pp | 0.00% +0.000 pp | USD3.35 +12.5% | 9 qtrs — |
| 26 | BANK OF NEW YORK MELLON CORP | 256.4K +50.7K (+24.7%) | 966.7K +635.5K (+191.9%) | 0.24% +0.028 pp | 0.00% +0.000 pp | USD2.49 +51.4% | 3 qtrs — |
| 27 | BARCLAYS PLC | 200.0K +200.0K (+100.0%) | 754.0K +754.0K (+100.0%) | 0.18% +0.185 pp | 0.00% +0.000 pp | USD3.77 +0.0% | 1 qtrs NEW |
| 28 | MARINER, LLC | 159.2K +50.3K (+46.3%) | 600.0K +424.8K (+242.5%) | 0.15% +0.036 pp | 0.00% +0.001 pp | USD2.14 +76.2% | 8 qtrs — |
| 29 | RHUMBLINE ADVISERS | 129.3K -7.3K (-5.4%) | 487.5K +267.5K (+121.6%) | 0.12% -0.019 pp | 0.00% +0.000 pp | USD2.19 +72.1% | 3 qtrs — |
| 30 | XTX TOPCO LTD | 118.4K +118.4K (+100.0%) | 446.5K +446.5K (+100.0%) | 0.11% +0.109 pp | 0.01% +0.012 pp | USD3.77 +0.0% | 10 qtrs — |
| 31 | BANK OF AMERICA CORP /DE/ | 100.9K +58.8K (+139.5%) | 380.5K +312.7K (+460.7%) | 0.09% +0.050 pp | 0.00% +0.000 pp | USD3.06 +23.2% | 9 qtrs — |
| 32 | CITADEL ADVISORS LLC | 96.7K +31.3K (+47.9%) | 364.6K +259.3K (+246.2%) | 0.09% +0.023 pp | 0.00% +0.000 pp | USD2.26 +66.8% | 20 qtrs — |
| 33 | LPL FINANCIAL LLC | 96.3K +25.3K (+35.6%) | 363.1K +248.7K (+217.4%) | 0.09% +0.017 pp | 0.00% +0.000 pp | USD1.88 +100.5% | 7 qtrs — |
| 34 | DEUTSCHE BANK AG\ | 91.7K -29.3K (-24.2%) | 345.7K +150.8K (+77.4%) | 0.08% -0.038 pp | 0.00% +0.000 pp | USD1.62 +132.7% | 3 qtrs — |
| 35 | TWO SIGMA ADVISERS, LP | 76.6K +76.6K (+100.0%) | 288.6K +288.6K (+100.0%) | 0.07% +0.071 pp | 0.00% +0.001 pp | USD3.77 +0.0% | 1 qtrs NEW |
| 36 | PRICE T ROWE ASSOCIATES INC /MD/ | 63.0K +15.1K (+31.4%) | 238.0K +160.0K (+205.1%) | 0.06% +0.010 pp | 0.00% +0.000 pp | USD2.57 +46.7% | 3 qtrs — |
| 37 | STONERIDGE INVESTMENT PARTNERS LLC | 61.3K +7.6K (+14.2%) | 231.0K +145.0K (+168.6%) | 0.06% +0.002 pp | 0.16% +0.102 pp | USD1.88 +100.5% | 2 qtrs — |
| 38 | INSTRUMENTAL WEALTH, LLC | 44.9K +— (+0.0%) | 221.0K +135.2K (+157.6%) | 0.04% -0.004 pp | 0.13% +0.072 pp | USD1.61 +134.2% | 2 qtrs — |
| 39 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 57.5K +12.9K (+28.9%) | 217.0K +145.1K (+201.8%) | 0.05% +0.008 pp | 0.00% +0.000 pp | USD2.54 +48.4% | 3 qtrs — |
| 40 | TWO SIGMA SECURITIES, LLC | 57.1K +57.1K (+100.0%) | 215.3K +215.3K (+100.0%) | 0.05% +0.053 pp | 0.03% +0.030 pp | USD3.77 +0.0% | 1 qtrs NEW |
| 41 | CITIGROUP INC | 55.5K +51.2K (+1,198.0%) | 209.1K +202.3K (+2,939.4%) | 0.05% +0.047 pp | 0.00% +0.000 pp | USD3.65 +3.3% | 3 qtrs — |
| 42 | CAITONG INTERNATIONAL ASSET MANAGEMENT CO., LTD | 55.1K +44.3K (+408.9%) | 207.8K +190.4K (+1,091.7%) | 0.05% +0.040 pp | 0.05% +0.039 pp | USD3.40 +10.9% | 3 qtrs — |
| 43 | INVESCO LTD. | 53.3K +3.1K (+6.2%) | 200.9K +120.1K (+148.7%) | 0.05% -0.002 pp | 0.00% +0.000 pp | USD2.28 +65.4% | 3 qtrs — |
| 44 | NORTHSTAR ASSET MANAGEMENT LLC | 50.0K +9.7K (+24.0%) | 188.5K +123.6K (+190.4%) | 0.05% +0.005 pp | 0.04% +0.026 pp | USD2.03 +85.7% | 2 qtrs — |
| 45 | ALLIANCEBERNSTEIN L.P. | 50.0K +— (+0.0%) | 188.3K +107.9K (+134.2%) | 0.05% -0.005 pp | 0.00% +0.000 pp | USD2.19 +72.1% | 3 qtrs — |
| 46 | JPMORGAN CHASE & CO | 49.5K +8.8K (+21.5%) | 186.5K +121.0K (+184.5%) | 0.05% +0.004 pp | 0.00% +0.000 pp | USD2.47 +52.6% | 3 qtrs — |
| 47 | UBS GROUP AG | 48.7K -36.3K (-42.7%) | 183.7K +46.9K (+34.3%) | 0.05% -0.041 pp | 0.00% +0.000 pp | USD1.96 +92.3% | 5 qtrs — |
| 48 | PENSIONMARK FINANCIAL GROUP, LLC | 44.1K +44.1K (+100.0%) | 166.3K +166.3K (+100.0%) | 0.04% +0.041 pp | 0.00% +0.003 pp | USD3.77 +0.0% | 1 qtrs NEW |
| 49 | INTECH INVESTMENT MANAGEMENT LLC | 40.3K -6.1K (-13.1%) | 151.8K +77.2K (+103.4%) | 0.04% -0.010 pp | 0.00% +0.001 pp | USD2.19 +72.1% | 3 qtrs — |
| 50 | SCIENTECH RESEARCH LLC | 38.7K +38.7K (+100.0%) | 146.1K +146.1K (+100.0%) | 0.04% +0.036 pp | 0.09% +0.092 pp | USD3.77 +0.0% | 1 qtrs NEW |
| 51 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 38.0K +4.6K (+13.6%) | 143.3K +89.5K (+166.1%) | 0.04% +0.001 pp | 0.00% +0.000 pp | USD2.38 +58.4% | 3 qtrs — |
| 52 | TYCHE WEALTH PARTNERS LLC | 37.5K +— (+0.0%) | 141.4K +81.0K (+134.2%) | 0.03% -0.004 pp | 0.02% +0.012 pp | USD1.61 +134.2% | 2 qtrs — |
| 53 | SG AMERICAS SECURITIES, LLC | 36.5K +17.1K (+88.2%) | 137.0K +106.0K (+341.9%) | 0.03% +0.014 pp | 0.00% +0.000 pp | USD2.93 +28.7% | 3 qtrs — |
| 54 | VISIONARY HORIZONS, LLC | 36.0K +36.0K (+100.0%) | 135.7K +135.7K (+100.0%) | 0.03% +0.033 pp | 0.07% +0.070 pp | USD3.77 +0.0% | 1 qtrs NEW |
| 55 | REGAL INVESTMENT ADVISORS LLC | 35.9K +35.9K (+100.0%) | 135.3K +135.3K (+100.0%) | 0.03% +0.033 pp | 0.01% +0.008 pp | USD3.77 +0.0% | 1 qtrs NEW |
| 56 | AXXCESS WEALTH MANAGEMENT, LLC | 35.4K +19.4K (+121.1%) | 133.3K +107.6K (+417.6%) | 0.03% +0.016 pp | 0.00% +0.001 pp | USD2.79 +35.1% | 2 qtrs — |
| 57 | POLICE & FIREMEN'S RETIREMENT SYSTEM OF NEW JERSEY | 34.7K +11.4K (+48.8%) | 131.0K +93.4K (+248.4%) | 0.03% +0.008 pp | 0.00% +0.001 pp | USD2.71 +39.1% | 3 qtrs — |
| 58 | EQUITABLE HOLDINGS, INC. | 32.1K +5.0K (+18.5%) | 120.9K +77.3K (+177.4%) | 0.03% +0.002 pp | 0.00% +0.001 pp | USD2.45 +53.9% | 22 qtrs — |
| 59 | GENESEE CAPITAL ADVISORS, LLC | 30.0K +— (+0.0%) | 113.1K +64.8K (+134.2%) | 0.03% -0.003 pp | 0.05% +0.025 pp | USD1.61 +134.2% | 2 qtrs — |
| 60 | COMMONWEALTH EQUITY SERVICES, LLC | 29.2K +13.4K (+84.5%) | 110.2K +84.2K (+324.0%) | 0.03% +0.011 pp | 0.00% +0.000 pp | USD2.53 +49.0% | 8 qtrs — |
| 61 | KESTRA ADVISORY SERVICES, LLC | 27.4K +1.0K (+3.8%) | 103.3K +60.8K (+143.0%) | 0.03% -0.002 pp | 0.00% +0.000 pp | USD1.69 +123.1% | 2 qtrs — |
| 62 | SCISSORTAIL WEALTH MANAGEMENT, LLC | 27.3K +— (+0.0%) | 103.0K +59.0K (+134.2%) | 0.03% -0.003 pp | 0.02% +0.014 pp | USD1.61 +134.2% | 2 qtrs — |
| 63 | METLIFE INVESTMENT MANAGEMENT, LLC | 27.2K -12.8K (-32.0%) | 102.5K +38.1K (+59.2%) | 0.03% -0.016 pp | 0.00% +0.000 pp | USD2.19 +72.1% | 3 qtrs — |
| 64 | BNP PARIBAS ARBITRAGE, SNC | 26.8K +7.1K (+36.1%) | 101.2K +69.4K (+218.6%) | 0.02% +0.005 pp | 0.00% +0.000 pp | USD2.41 +56.4% | 3 qtrs — |
| 65 | SEI INVESTMENTS CO | 26.6K +— (+0.0%) | 100.2K +57.4K (+134.2%) | 0.02% -0.002 pp | 0.00% +0.000 pp | USD1.61 +134.2% | 2 qtrs — |
| 66 | BLAIR WILLIAM & CO/IL | 26.0K +10.0K (+62.5%) | 98.0K +72.3K (+280.5%) | 0.02% +0.008 pp | 0.00% +0.000 pp | USD2.80 +34.6% | 3 qtrs — |
| 67 | MILLINGTON FINANCIAL ADVISORS, LLC | 25.0K +25.0K (+100.0%) | 93.3K +93.3K (+100.0%) | 0.02% +0.023 pp | 0.04% +0.041 pp | USD3.77 +0.0% | 1 qtrs NEW |
| 68 | JAFFETILCHIN INVESTMENT PARTNERS, LLC | 24.3K +24.3K (+100.0%) | 91.8K +91.8K (+100.0%) | 0.02% +0.023 pp | 0.01% +0.005 pp | USD3.77 +0.0% | 1 qtrs NEW |
| 69 | TRUSTMARK NATIONAL BANK TRUST DEPARTMENT | 24.0K -12.5K (-34.3%) | 90.5K +31.7K (+53.9%) | 0.02% -0.015 pp | 0.01% +0.002 pp | USD1.61 +134.2% | 2 qtrs — |
| 70 | ADVISOR GROUP HOLDINGS, INC. | 23.7K +16.0K (+209.3%) | 89.3K +74.6K (+507.2%) | 0.02% +0.014 pp | 0.00% +0.000 pp | USD3.30 +14.2% | 21 qtrs — |
| 71 | PROSHARE ADVISORS LLC | 22.6K +5.4K (+31.5%) | 85.3K +57.6K (+207.8%) | 0.02% +0.003 pp | 0.00% +0.000 pp | USD2.57 +46.7% | 3 qtrs — |
| 72 | VOYA INVESTMENT MANAGEMENT LLC | 21.0K +3.6K (+20.6%) | 79.3K +51.2K (+182.4%) | 0.02% +0.002 pp | 0.00% +0.000 pp | USD2.46 +53.3% | 3 qtrs — |
| 73 | SIMON QUICK ADVISORS, LLC | 20.0K +— (+0.0%) | 75.4K +43.2K (+134.2%) | 0.02% -0.002 pp | 0.00% +0.002 pp | USD2.19 +72.1% | 3 qtrs — |
| 74 | VERITION FUND MANAGEMENT LLC | 19.5K +19.5K (+100.0%) | 73.5K +73.5K (+100.0%) | 0.02% +0.018 pp | 0.00% +0.000 pp | USD3.77 +0.0% | 1 qtrs NEW |
| 75 | PRIVATE ADVISOR GROUP, LLC | 18.2K +18.2K (+100.0%) | 68.6K +68.6K (+100.0%) | 0.02% +0.017 pp | 0.00% +0.000 pp | USD3.77 +0.0% | 1 qtrs NEW |
| 76 | VICTORY CAPITAL MANAGEMENT INC | 16.4K +4.5K (+37.8%) | 61.6K +42.5K (+222.6%) | 0.02% +0.003 pp | 0.00% +0.000 pp | USD2.62 +43.9% | 3 qtrs — |
| 77 | GRANGE CAPITAL, LLC | 16.0K +2.5K (+18.5%) | 60.3K +38.6K (+177.5%) | 0.01% +0.001 pp | 0.06% +0.037 pp | USD1.50 +151.3% | 4 qtrs — |
| 78 | ELCO MANAGEMENT CO., LLC | 14.6K +600.0 (+4.3%) | 55.1K +32.5K (+144.2%) | 0.01% -0.001 pp | 0.03% +0.023 pp | USD1.70 +121.8% | 2 qtrs — |
| 79 | BOOTHBAY FUND MANAGEMENT, LLC | 13.8K +13.8K (+100.0%) | 52.0K +52.0K (+100.0%) | 0.01% +0.013 pp | 0.00% +0.001 pp | USD3.77 +0.0% | 1 qtrs NEW |
| 80 | SQUAREPOINT OPS LLC | 13.3K -32.9K (-71.2%) | 50.1K -24.3K (-32.6%) | 0.01% -0.035 pp | 0.00% +0.000 pp | USD1.81 +108.3% | 3 qtrs — |
| 81 | STIFEL FINANCIAL CORP | 13.0K +13.0K (+100.0%) | 49.1K +49.1K (+100.0%) | 0.01% +0.012 pp | 0.00% +0.000 pp | USD3.77 +0.0% | 1 qtrs NEW |
| 82 | LEGAL & GENERAL GROUP PLC | 13.0K +2.4K (+22.6%) | 49.1K +32.0K (+187.2%) | 0.01% +0.001 pp | 0.00% +0.000 pp | USD2.48 +52.0% | 3 qtrs — |
| 83 | EWA, LLC | 12.8K +12.8K (+100.0%) | 48.2K +48.2K (+100.0%) | 0.01% +0.012 pp | 0.01% +0.012 pp | USD3.77 +0.0% | 1 qtrs NEW |
| 84 | — | 12.5K +12.5K (+100.0%) | 47.1K +47.1K (+100.0%) | 0.01% +0.012 pp | 0.04% +0.039 pp | USD3.77 +0.0% | 1 qtrs NEW |
| 85 | CAMBRIDGE INVESTMENT RESEARCH ADVISORS, INC. | 12.4K -7.6K (-37.8%) | 47.0K +15.0K (+46.9%) | 0.01% -0.009 pp | 0.00% +0.000 pp | USD1.61 +134.2% | 2 qtrs — |
| 86 | CWM, LLC | 11.8K +6.5K (+124.7%) | 44.0K +36.0K (+450.0%) | 0.01% +0.006 pp | 0.00% +0.000 pp | USD2.81 +34.2% | 2 qtrs — |
| 87 | CALTON & ASSOCIATES, INC. | 11.0K +— (+0.0%) | 41.5K +23.8K (+134.2%) | 0.01% -0.001 pp | 0.01% +0.003 pp | USD1.08 +249.1% | 6 qtrs — |
| 88 | MONEY CONCEPTS CAPITAL CORP | 10.6K +10.6K (+100.0%) | 40.0K +40.0K (+100.0%) | 0.01% +0.010 pp | 0.00% +0.002 pp | USD3.77 +0.0% | 1 qtrs NEW |
| 89 | JEFFERIES FINANCIAL GROUP INC. | 10.1K +10.1K (+100.0%) | 38.1K +38.1K (+100.0%) | 0.01% +0.009 pp | 0.00% +0.000 pp | USD3.77 +0.0% | 1 qtrs NEW |
| 90 | CONCURRENT INVESTMENT ADVISORS, LLC | 10.1K +10.1K (+100.0%) | 38.0K +38.0K (+100.0%) | 0.01% +0.009 pp | 0.00% +0.000 pp | USD3.77 +0.0% | 1 qtrs NEW |
| 91 | DANSKE BANK A/S | 100.0K +100.0K (+100.0%) | 35.0K +35.0K (+100.0%) | 0.09% +0.092 pp | 0.00% +0.000 pp | USD3.77 +0.0% | 1 qtrs NEW |
Ownership breakdown by holder
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
7
Sells
0
Shares acquired
850.0K
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+850,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-01-07 | Wasman Jane | Director | A-Award | A | Common Stock | 50,000 | 0.00 | — | 92,900 | D | ↗ |
| 2026-01-07 | Varian John | Director | A-Award | A | Common Stock | 50,000 | 0.00 | — | 72,900 | D | ↗ |
| 2026-01-07 | VAN NOSTRAND ROBERT L | Director | A-Award | A | Common Stock | 50,000 | 0.00 | — | 82,900 | D | ↗ |
| 2026-01-07 | SCHEINBERG DAVID A | Director | A-Award | A | Common Stock | 50,000 | 0.00 | — | 73,082 | D | ↗ |
| 2026-01-07 | Kalin Katherine Bach | Director | A-Award | A | Common Stock | 50,000 | 0.00 | — | 154,400 | D | ↗ |
| 2026-01-07 | CICIC DRAGAN | Officer | A-Award | A | Common Stock | 300,000 | 0.00 | — | 557,805 | D | ↗ |
| 2026-01-07 | Burns John Thomas | Officer | A-Award | A | Common Stock | 300,000 | 0.00 | — | 554,327 | D | ↗ |
| 2025-12-03 | Stergiou Angelos M. | Director / Officer | J-Other | D | Common Stock | 187,066 | 1.50 | 280.6K | 686,966 | D | ↗ |
| 2025-12-03 | CICIC DRAGAN | Officer | J-Other | D | Common Stock | 63,800 | 1.50 | 95.7K | 257,805 | D | ↗ |
| 2025-12-03 | Burns John Thomas | Officer | J-Other | D | Common Stock | 58,592 | 1.50 | 87.9K | 254,327 | D | ↗ |
| 2025-11-19 | Kalin Katherine Bach | Director | P-Purchase | A | Common Stock | 63,400 | 1.59 | 100.8K | 104,400 | D | ↗ |
| 2025-06-12 | VAN NOSTRAND ROBERT L | Director | P-Purchase | A | Common Stock | 10,000 | 1.48 | 14.8K | 20,400 | D | ↗ |
| 2025-05-30 | Wasman Jane | Director | P-Purchase | A | Common Stock | 20,000 | 1.69 | 33.8K | 30,400 | D | ↗ |
| 2025-05-22 | Kalin Katherine Bach | Director | P-Purchase | A | Common Stock | 20,000 | 1.80 | 36.0K | 41,000 | D | ↗ |
| 2025-01-10 | Wasman Jane | Director | A-Award | A | Stock Option (Right to Buy) | 18,500 | 0.95 | 17.6K | 18,500 | D | ↗ |
| 2025-01-10 | Varian John | Director | A-Award | A | Stock Option (Right to Buy) | 18,500 | 0.95 | 17.6K | 18,500 | D | ↗ |
| 2025-01-10 | VAN NOSTRAND ROBERT L | Director | A-Award | A | Stock Option (Right to Buy) | 18,500 | 0.95 | 17.6K | 18,500 | D | ↗ |
| 2025-01-10 | Stergiou Angelos M. | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 385,750 | 0.95 | 367.4K | 385,750 | D | ↗ |
| 2025-01-10 | SCHEINBERG DAVID A | Director | A-Award | A | Stock Option (Right to Buy) | 18,500 | 0.95 | 17.6K | 18,500 | D | ↗ |
| 2025-01-10 | Kalin Katherine Bach | Director | A-Award | A | Stock Option (Right to Buy) | 18,500 | 0.95 | 17.6K | 18,500 | D | ↗ |
| 2025-01-10 | CICIC DRAGAN | Officer | A-Award | A | Common Stock | 113,000 | 0.00 | — | 228,328 | D | ↗ |
| 2025-01-10 | Burns John Thomas | Officer | A-Award | A | Stock Option (Right to Buy) | 169,500 | 0.95 | 161.4K | 169,500 | D | ↗ |
| 2024-12-04 | Stergiou Angelos M. | Director / Officer | J-Other | D | Common Stock | 28,289 | 1.13 | 32.0K | 358,132 | D | ↗ |
| 2024-12-04 | CICIC DRAGAN | Officer | J-Other | D | Common Stock | 8,256 | 1.13 | 9.3K | 115,328 | D | ↗ |
| 2024-12-04 | Burns John Thomas | Officer | J-Other | D | Common Stock | 7,165 | 1.13 | 8.1K | 104,762 | D | ↗ |
| 2024-06-20 | CICIC DRAGAN | Officer | — | D | Common Stock | 0 | 0.00 | — | 118,584 | — | ↗ |
| 2024-01-22 | Wasman Jane | Director | A-Award | A | Common Stock | 6,000 | 0.00 | — | 10,400 | — | ↗ |
| 2024-01-22 | WOOD BARBARA A | Officer | A-Award | A | Stock Option (Right to Buy) | 50,000 | 0.52 | 26.0K | 50,000 | — | ↗ |
| 2024-01-22 | Varian John | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 0.52 | 5.2K | 10,000 | — | ↗ |
| 2024-01-22 | VAN NOSTRAND ROBERT L | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 0.52 | 5.2K | 10,000 | — | ↗ |
| 2024-01-22 | Stergiou Angelos M. | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 238,500 | 0.52 | 123.9K | 238,500 | — | ↗ |
| 2024-01-22 | SCHEINBERG DAVID A | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 0.52 | 5.2K | 10,000 | — | ↗ |
| 2024-01-22 | Kalin Katherine Bach | Director | A-Award | A | Common Stock | 6,000 | 0.00 | — | 8,500 | — | ↗ |
| 2024-01-22 | Francomano Robert | Officer | A-Award | A | Common Stock | 20,000 | 0.00 | — | 40,918 | — | ↗ |
| 2024-01-22 | Burns John Thomas | Officer | A-Award | A | Stock Option (Right to Buy) | 75,000 | 0.52 | 39.0K | 75,000 | — | ↗ |
| 2023-12-06 | WOOD BARBARA A | Officer | J-Other | D | Class A Common Stock | 4,119 | 1.08 | 4.4K | 82,225 | — | ↗ |
| 2023-12-06 | Stergiou Angelos M. | Director / Officer | J-Other | D | Class A Common Stock | 12,268 | 1.08 | 13.2K | 217,421 | — | ↗ |
| 2023-12-06 | Francomano Robert | Officer | J-Other | D | Class A Common Stock | 1,082 | 1.08 | 1.2K | 20,918 | — | ↗ |
| 2023-12-06 | Burns John Thomas | Officer | J-Other | D | Class A Common Stock | 2,929 | 1.08 | 3.2K | 54,927 | — | ↗ |
| 2023-02-02 | Wasman Jane | Director | A-Award | A | Common Stock | 2,500 | 0.00 | — | 4,400 | — | ↗ |
| 2023-02-02 | WOOD BARBARA A | Officer | A-Award | A | Common Stock | 20,000 | 0.00 | — | 76,344 | — | ↗ |
| 2023-02-02 | Varian John | Director | A-Award | A | Common Stock | 2,500 | 0.00 | — | 4,400 | — | ↗ |
| 2023-02-02 | VAN NOSTRAND ROBERT L | Director | A-Award | A | Common Stock | 2,500 | 0.00 | — | 4,400 | — | ↗ |
| 2023-02-02 | Stergiou Angelos M. | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 217,500 | 3.34 | 726.5K | 217,500 | — | ↗ |
| 2023-02-02 | SCHEINBERG DAVID A | Director | A-Award | A | Common Stock | 2,500 | 0.00 | — | 4,582 | — | ↗ |
| 2023-02-02 | Kalin Katherine Bach | Director | A-Award | A | Common Stock | 2,500 | 0.00 | — | 2,500 | — | ↗ |
| 2023-02-02 | Francomano Robert | Officer | A-Award | A | Stock Option (Right to Buy) | 45,000 | 3.34 | 150.3K | 45,000 | — | ↗ |
| 2023-02-02 | Burns John Thomas | Officer | A-Award | A | Common Stock | 20,000 | 0.00 | — | 49,347 | — | ↗ |
| 2022-12-05 | WOOD BARBARA A | Officer | S-Sale | D | Class A Common Stock | 2,153 | 2.59 | 5.6K | 56,344 | — | ↗ |
| 2022-12-05 | Stergiou Angelos M. | Officer | S-Sale | D | Class A Common Stock | 6,494 | 2.61 | 16.9K | 161,689 | — | ↗ |
| 2022-12-05 | Burns John Thomas | Officer | S-Sale | D | Class A Common Stock | 1,159 | 2.59 | 3.0K | 29,347 | — | ↗ |
| 2022-08-13 | Kalin Katherine Bach | Director | A-Award | A | Stock Option (Right to Buy) | 19,000 | 0.00 | — | 19,000 | — | ↗ |
| 2022-03-14 | Francomano Robert | Officer | A-Award | A | Stock Option (Right to Buy) | 100,000 | 0.00 | — | 100,000 | — | ↗ |
| 2022-01-31 | Wasman Jane | Director | A-Award | A | Common Stock | 1,900 | 0.00 | — | 1,900 | — | ↗ |
| 2022-01-31 | WOOD BARBARA A | Officer | A-Award | A | Common Stock | 13,000 | 0.00 | — | 55,028 | — | ↗ |
| 2022-01-31 | Varian John | Director | A-Award | A | Common Stock | 1,900 | 0.00 | — | 1,900 | — | ↗ |
| 2022-01-31 | VAN NOSTRAND ROBERT L | Director | A-Award | A | Common Stock | 1,900 | 0.00 | — | 1,900 | — | ↗ |
| 2022-01-31 | Stergiou Angelos M. | Officer | A-Award | A | Stock Option (Right to Buy) | 165,000 | 5.34 | 881.1K | 165,000 | — | ↗ |
| 2022-01-31 | SCHEINBERG DAVID A | Director | A-Award | A | Common Stock | 1,900 | 0.00 | — | 2,082 | — | ↗ |
| 2022-01-31 | Burns John Thomas | Officer | A-Award | A | Stock Option (Right to Buy) | 36,000 | 5.34 | 192.2K | 36,000 | — | ↗ |
| 2021-12-02 | WOOD BARBARA A | Officer | S-Sale | D | Common Stock | 847 | 6.25 | 5.3K | 42,028 | — | ↗ |
| 2021-12-02 | Stergiou Angelos M. | Director / Officer | S-Sale | D | Common Stock | 2,120 | 6.25 | 13.3K | 121,167 | — | ↗ |
| 2021-12-02 | Burns John Thomas | Officer | S-Sale | D | Common Stock | 231 | 6.27 | 1.4K | 17,644 | — | ↗ |
| 2021-03-04 | Wasman Jane | Director | A-Award | A | Stock Option (Right to Buy) | 7,500 | 8.00 | 60.0K | 7,500 | — | ↗ |
| 2021-03-04 | WOOD BARBARA A | Officer | A-Award | A | Stock Option (Right to Buy) | 47,250 | 8.00 | 378.0K | 47,250 | — | ↗ |
| 2021-03-04 | Varian John | Director | A-Award | A | Stock Option (Right to Buy) | 7,500 | 8.00 | 60.0K | 7,500 | — | ↗ |
| 2021-03-04 | VAN NOSTRAND ROBERT L | Director | A-Award | A | Stock Option (Right to Buy) | 7,500 | 8.00 | 60.0K | 7,500 | — | ↗ |
| 2021-03-04 | Stergiou Angelos M. | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 118,500 | 8.00 | 948.0K | 118,500 | — | ↗ |
| 2021-03-04 | SCHEINBERG DAVID A | Director | A-Award | A | Stock Option (Right to Buy) | 7,500 | 8.00 | 60.0K | 7,500 | — | ↗ |
| 2021-03-04 | Burns John Thomas | Officer | A-Award | A | Stock Option (Right to Buy) | 17,250 | 8.00 | 138.0K | 17,250 | — | ↗ |
| 2020-03-12 | Wasman Jane | Director | A-Award | A | Stock Option (Right to Buy) | 6,500 | 1.89 | 12.3K | 6,500 | — | ↗ |
| 2020-03-12 | WOOD BARBARA A | Officer | A-Award | A | Stock Option (Right to Buy) | 25,000 | 1.89 | 47.3K | 25,000 | — | ↗ |
| 2020-03-12 | Varian John | Director | A-Award | A | Stock Option (Right to Buy) | 6,500 | 1.89 | 12.3K | 6,500 | — | ↗ |
| 2020-03-12 | VAN NOSTRAND ROBERT L | Director | A-Award | A | Stock Option (Right to Buy) | 6,500 | 1.89 | 12.3K | 6,500 | — | ↗ |
| 2020-03-12 | Stergiou Angelos M. | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 70,000 | 1.89 | 132.3K | 70,000 | — | ↗ |
| 2020-03-12 | SCHEINBERG DAVID A | Director | A-Award | A | Stock Option (Right to Buy) | 6,500 | 1.89 | 12.3K | 6,500 | — | ↗ |
| 2020-03-12 | Burns John Thomas | Officer | A-Award | A | Stock Option (Right to Buy) | 10,000 | 1.89 | 18.9K | 10,000 | — | ↗ |
| 2019-03-14 | Wasman Jane | Director | A-Award | A | Stock Option (Right to Buy) | 25,000 | 1.38 | 34.5K | 25,000 | — | ↗ |
| 2019-03-14 | WOOD BARBARA A | Officer | A-Award | A | Stock Option (Right to Buy) | 165,000 | 1.38 | 227.7K | 165,000 | — | ↗ |
| 2019-03-14 | Varian John | Director | A-Award | A | Stock Option (Right to Buy) | 25,000 | 1.38 | 34.5K | 25,000 | — | ↗ |
| 2019-03-14 | VAN NOSTRAND ROBERT L | Director | A-Award | A | Stock Option (Right to Buy) | 25,000 | 1.38 | 34.5K | 25,000 | — | ↗ |
| 2019-03-14 | Stergiou Angelos M. | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 425,000 | 1.38 | 586.5K | 425,000 | — | ↗ |
| 2019-03-14 | Sarlis Nicholas J. | Officer | A-Award | A | Stock Option (Right to Buy) | 50,000 | 1.38 | 69.0K | 50,000 | — | ↗ |
| 2019-03-14 | SCHEINBERG DAVID A | Director | A-Award | A | Stock Option (Right to Buy) | 25,000 | 1.38 | 34.5K | 25,000 | — | ↗ |
| 2019-03-14 | Ghiglieri Stephen F | Director | A-Award | A | Stock Option (Right to Buy) | 25,000 | 1.38 | 34.5K | 25,000 | — | ↗ |
| 2019-03-14 | Burns John Thomas | Officer | A-Award | A | Stock Option (Right to Buy) | 90,000 | 1.38 | 124.2K | 90,000 | — | ↗ |
| 2018-12-31 | Stergiou Angelos M. | Director / Officer | S-Sale | D | Common Stock | 23,277 | 1.25 | 29.2K | 426,858 | — | ↗ |
| 2018-12-17 | Burns John Thomas | Officer | — | D | Common Stock | 0 | 0.00 | — | 18 | — | ↗ |
| 2018-09-24 | Lopez Fabio | Director | J-Other | D | Common Stock | 325,799 | 0.00 | — | 0 | — | ↗ |
| 2018-06-12 | Wasman Jane | Director | A-Award | A | Stock Option (Right to Buy) | 5,500 | 5.23 | 28.8K | 5,500 | — | ↗ |
| 2018-06-12 | Varian John | Director | A-Award | A | Stock Option (Right to Buy) | 5,500 | 0.00 | — | 5,500 | — | ↗ |
| 2018-06-12 | VAN NOSTRAND ROBERT L | Director | A-Award | A | Stock Option (Right to Buy) | 5,500 | 5.23 | 28.8K | 5,500 | — | ↗ |
| 2018-06-12 | SCHEINBERG DAVID A | Director | A-Award | A | Stock Option (Right to Buy) | 5,500 | 5.23 | 28.8K | 5,500 | — | ↗ |
| 2018-06-12 | Lopez Fabio | Director / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 5,500 | 5.23 | 28.8K | 5,500 | — | ↗ |
| 2018-06-12 | Ghiglieri Stephen F | Director | A-Award | A | Stock Option (Right to Buy) | 5,500 | 5.23 | 28.8K | 5,500 | — | ↗ |
| 2018-04-20 | Mack Gene | Officer | A-Award | A | Stock Option (Right to Buy) | 40,000 | 5.38 | 215.2K | 40,000 | — | ↗ |
| 2018-03-14 | WOOD BARBARA A | Officer | A-Award | A | Stock Option (Right to Buy) | 50,000 | 5.10 | 255.0K | 50,000 | — | ↗ |
| 2018-03-13 | Wasman Jane | Director | A-Award | A | Stock Option (Right to Buy) | 11,000 | 5.24 | 57.6K | 11,000 | — | ↗ |
| 2018-03-13 | Varian John | Director | A-Award | A | Stock Option (Right to Buy) | 11,000 | 5.24 | 57.6K | 11,000 | — | ↗ |
| 2018-03-13 | VAN NOSTRAND ROBERT L | Director | A-Award | A | Stock Option (Right to Buy) | 11,000 | 5.24 | 57.6K | 11,000 | — | ↗ |
| 2018-03-13 | Torre Gregory M | Officer | A-Award | A | Stock Option (Right to Buy) | 30,000 | 5.24 | 157.2K | 30,000 | — | ↗ |
| 2018-03-13 | Stergiou Angelos M. | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 95,000 | 5.24 | 497.8K | 95,000 | — | ↗ |
| 2018-03-13 | Sarlis Nicholas J. | Officer | A-Award | A | Stock Option (Right to Buy) | 70,000 | 5.24 | 366.8K | 70,000 | — | ↗ |
| 2018-03-13 | SCHEINBERG DAVID A | Director | A-Award | A | Stock Option (Right to Buy) | 11,000 | 5.24 | 57.6K | 11,000 | — | ↗ |
| 2018-03-13 | Lopez Fabio | Director / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 11,000 | 5.24 | 57.6K | 11,000 | — | ↗ |
| 2018-03-13 | Ghiglieri Stephen F | Director | A-Award | A | Stock Option (Right to Buy) | 11,000 | 5.24 | 57.6K | 11,000 | — | ↗ |
| 2017-12-29 | Wasman Jane | Director | — | D | Common Stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-12-29 | Varian John | Director | — | D | Common Stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-12-29 | VAN NOSTRAND ROBERT L | Director | — | D | Common Stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-12-29 | Torre Gregory M | Officer | — | D | Common Stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-12-29 | Stergiou Andelos M. | Director / Officer | — | D | Common Stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-12-29 | Sarlis Nicholas J. | Officer | — | D | Common Stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-12-29 | SCHEINBERG DAVID A | Director | — | D | Common Stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-12-29 | Lopez Fabio | Director | A-Award | A | Common Stock | 149,766 | 0.00 | — | 149,766 | — | ↗ |
| 2017-12-29 | Krylov Aleksey N. | Officer | — | D | Common Stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-10-10 | Nisi Rudolph | Director | A-Award | A | Common Stock | 17,130 | 0.38 | 6.5K | 42,918 | — | ↗ |
| 2017-10-10 | Hillsberg Sanford | Director | A-Award | A | Common Stock | 20,997 | 0.38 | 8.0K | 56,950 | — | ↗ |
| 2017-10-10 | GRAY MARY ANN | Director | A-Award | A | Common Stock | 15,472 | 0.38 | 5.9K | 39,167 | — | ↗ |
| 2017-10-10 | GALLIKER STEPHEN S | Director | A-Award | A | Common Stock | 13,814 | 0.38 | 5.2K | 36,039 | — | ↗ |
| 2017-10-10 | Einhorn Irving M. | Director | A-Award | A | Common Stock | 14,366 | 0.38 | 5.5K | 34,690 | — | ↗ |
| 2017-10-10 | Chin Richard | Director | A-Award | A | Common Stock | 12,708 | 0.38 | 4.8K | 31,339 | — | ↗ |
| 2017-10-10 | Ashton William | Director | A-Award | A | Common Stock | 15,472 | 0.38 | 5.9K | 38,154 | — | ↗ |
| 2017-07-06 | Nisi Rudolph | Director | A-Award | A | Common Stock | 10,924 | 0.59 | 6.4K | 25,788 | — | ↗ |
| 2017-07-06 | Hillsberg Sanford | Director | A-Award | A | Common Stock | 13,390 | 0.59 | 7.9K | 35,953 | — | ↗ |
| 2017-07-06 | GRAY MARY ANN | Director | A-Award | A | Common Stock | 9,866 | 0.59 | 5.8K | 23,695 | — | ↗ |
| 2017-07-06 | GALLIKER STEPHEN S | Director | A-Award | A | Common Stock | 8,809 | 0.59 | 5.2K | 22,225 | — | ↗ |
| 2017-07-06 | Einhorn Irving M. | Director | A-Award | A | Common Stock | 9,161 | 0.59 | 5.4K | 20,114 | — | ↗ |
| 2017-07-06 | Chin Richard | Director | A-Award | A | Common Stock | 8,104 | 0.59 | 4.8K | 18,631 | — | ↗ |
| 2017-07-06 | Ashton William | Director | A-Award | A | Common Stock | 9,866 | 0.59 | 5.8K | 22,682 | — | ↗ |
| 2017-06-20 | Nisi Rudolph | Director | S-Sale | D | Common Stock | 500 | 0.55 | 273.05 | 14,864 | — | ↗ |
| 2017-06-08 | Nisi Rudolph | Director | A-Award | A | Stock Option (right to buy) | 5,000 | 0.55 | 2.8K | 5,000 | — | ↗ |
| 2017-06-08 | Hillsberg Sanford | Director | A-Award | A | Stock Option (right to buy) | 5,000 | 0.55 | 2.8K | 5,000 | — | ↗ |
| 2017-06-08 | GRAY MARY ANN | Director | A-Award | A | Stock Option (right to buy) | 5,000 | 0.55 | 2.8K | 5,000 | — | ↗ |
| 2017-06-08 | GALLIKER STEPHEN S | Director | A-Award | A | Stock Option (right to buy) | 5,000 | 0.55 | 2.8K | 5,000 | — | ↗ |
| 2017-06-08 | Einhorn Irving M. | Director | A-Award | A | Stock Option (right to buy) | 5,000 | 0.55 | 2.8K | 5,000 | — | ↗ |
| 2017-06-08 | Chin Richard | Director | A-Award | A | Stock Option (right to buy) | 5,000 | 0.55 | 2.8K | 5,000 | — | ↗ |
| 2017-06-08 | Ashton William | Director | A-Award | A | Stock Option (right to buy) | 5,000 | 0.55 | 2.8K | 5,000 | — | ↗ |
| 2017-04-10 | Hillsberg Sanford | Director | A-Award | A | Common Stock | 13,394 | 0.59 | 7.9K | 22,563 | — | ↗ |
| 2017-04-10 | GRAY MARY ANN | Director | A-Award | A | Common Stock | 8,815 | 0.59 | 5.2K | 13,829 | — | ↗ |
| 2017-04-10 | GALLIKER STEPHEN S | Director | A-Award | A | Common Stock | 9,865 | 0.59 | 5.8K | 13,416 | — | ↗ |
| 2017-04-10 | Einhorn Irving M. | Director | A-Award | A | Common Stock | 8,638 | 0.59 | 5.1K | 10,953 | — | ↗ |
| 2017-04-10 | Chin Richard | Director | A-Award | A | Common Stock | 8,107 | 0.59 | 4.8K | 10,527 | — | ↗ |
| 2017-04-10 | Ashton William | Director | A-Award | A | Common Stock | 9,870 | 0.59 | 5.8K | 12,816 | — | ↗ |
| 2017-02-08 | Hudson Bay Capital Management LP | 10% Owner | — | I | Call Options (obligation to sell) | 3,400 | 3.00 | 10.2K | 0 | — | ↗ |
| 2017-02-06 | Knapp Thomas J | Officer | A-Award | A | Stock Option (right to buy) | 10,000 | 1.41 | 14.1K | 10,000 | — | ↗ |
| 2017-01-20 | Nisi Rudolph | Director | A-Award | A | Common Stock | 3,262 | 1.98 | 6.5K | 4,437 | — | ↗ |
| 2017-01-20 | Hillsberg Sanford | Director | A-Award | A | Common Stock | 3,998 | 1.98 | 7.9K | 9,169 | — | ↗ |
| 2017-01-20 | GRAY MARY ANN | Director | A-Award | A | Common Stock | 2,525 | 1.98 | 5.0K | 5,004 | — | ↗ |
| 2017-01-20 | Einhorn Irving M. | Director | A-Award | A | Common Stock | 2,525 | 1.98 | 5.0K | 2,525 | — | ↗ |
| 2017-01-20 | Chin Richard | Director | A-Award | A | Common Stock | 2,420 | 1.98 | 4.8K | 2,420 | — | ↗ |
| 2017-01-17 | Nejadnik Bijan | Officer | A-Award | A | Stock Option (right to buy) | 30,000 | 1.81 | 54.3K | 30,000 | — | ↗ |
| 2017-01-17 | Knapp Thomas J | Officer | A-Award | A | Stock Option (right to buy) | 5,000 | 1.81 | 9.1K | 5,000 | — | ↗ |
| 2017-01-17 | Burns John Thomas | Officer | A-Award | A | Stock Option (right to buy) | 15,000 | 1.81 | 27.2K | 15,000 | — | ↗ |
| 2016-11-01 | Ghiglieri Stephen F | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2016-10-25 | Knapp Thomas J | Officer | A-Award | A | Stock Option (right to buy) | 102,000 | 0.29 | 29.6K | 102,000 | — | ↗ |
| 2016-07-14 | Nisi Rudolph | Director | A-Award | A | Stock Option (right to buy) | 100,000 | 0.41 | 41.0K | 100,000 | — | ↗ |
| 2016-07-14 | Hillsberg Sanford | Director | A-Award | A | Stock Option (right to buy) | 100,000 | 0.41 | 41.0K | 100,000 | — | ↗ |
| 2016-07-14 | GRAY MARY ANN | Director | A-Award | A | Stock Option (right to buy) | 100,000 | 0.41 | 41.0K | 100,000 | — | ↗ |
| 2016-07-14 | GALLIKER STEPHEN S | Director | A-Award | A | Stock Option (right to buy) | 100,000 | 0.00 | — | 100,000 | — | ↗ |
| 2016-07-14 | Einhorn Irving M. | Director | A-Award | A | Stock Option (right to buy) | 100,000 | 0.41 | 41.0K | 100,000 | — | ↗ |
| 2016-07-14 | Chin Richard | Director | A-Award | A | Stock Option (right to buy) | 100,000 | 0.41 | 41.0K | 100,000 | — | ↗ |
| 2016-07-14 | Ashton William | Director | A-Award | A | Stock Option (right to buy) | 100,000 | 0.41 | 41.0K | 100,000 | — | ↗ |
| 2016-07-01 | SCHWARTZ MARK W. | Officer | J-Other | A | Common Stock | 8,503 | 0.40 | 3.4K | 439,978 | — | ↗ |
| 2016-07-01 | Nejadnik Bijan | Officer | J-Other | A | Common Stock | 8,503 | 0.40 | 3.4K | 8,503 | — | ↗ |
| 2016-07-01 | Burns John Thomas | Officer | J-Other | A | Common Stock | 8,503 | 0.40 | 3.4K | 10,899 | — | ↗ |
| 2016-04-25 | GRAY MARY ANN | Director | A-Award | A | Stock Option (right to buy) | 200,000 | 1.40 | 280.0K | 200,000 | — | ↗ |
| 2016-02-23 | Burns John Thomas | Officer | — | D | Common Stock | 0 | 0.00 | — | 2,396 | — | ↗ |
| 2016-01-07 | Hudson Bay Capital Management LP | 10% Owner | — | I | Warrant (right to buy) | 54,545 | 28.40 | 1.55M | 0 | — | ↗ |
| 2015-12-18 | SCHWARTZ MARK W. | Officer | A-Award | A | Stock Option (right to buy) | 1,250,000 | 0.00 | — | 1,250,000 | — | ↗ |
| 2015-12-18 | Nejadnik Bijan | Officer | A-Award | A | Stock Option (right to buy) | 50,000 | 0.00 | — | 50,000 | — | ↗ |
| 2015-12-18 | Knapp Thomas J | Officer | A-Award | A | Stock Option (right to buy) | 225,000 | 1.50 | 337.5K | 225,000 | — | ↗ |
| 2015-10-30 | Nejadnik Bijan | Officer | A-Award | A | Stock Option (right to buy) | 350,000 | 1.68 | 588.0K | 350,000 | — | ↗ |
| 2015-06-25 | Knapp Thomas J | Officer | A-Award | A | Stock Option (right to buy) | 40,000 | 1.83 | 73.2K | 40,000 | — | ↗ |
| 2015-06-19 | Nisi Rudolph | Director | A-Award | A | Stock Option (right to buy) | 100,000 | 1.77 | 177.0K | 100,000 | — | ↗ |
| 2015-06-19 | KRIEGSMAN STEVEN A | Director | A-Award | A | Stock Option (right to buy) | 100,000 | 1.77 | 177.0K | 100,000 | — | ↗ |
| 2015-06-19 | Hillsberg Sanford | Director | A-Award | A | Stock Option (right to buy) | 100,000 | 1.77 | 177.0K | 100,000 | — | ↗ |
| 2015-06-19 | GALLIKER STEPHEN S | Director | A-Award | A | Stock Option (right to buy) | 100,000 | 1.77 | 177.0K | 100,000 | — | ↗ |
| 2015-06-19 | Einhorn Irving M. | Director | A-Award | A | Stock Option (right to buy) | 100,000 | 1.77 | 177.0K | 100,000 | — | ↗ |
| 2015-06-19 | Chin Richard | Director | A-Award | A | Stock Option (right to buy) | 100,000 | 1.77 | 177.0K | 100,000 | — | ↗ |
| 2015-06-19 | Ashton William | Director | A-Award | A | Stock Option (right to buy) | 100,000 | 1.77 | 177.0K | 100,000 | — | ↗ |
| 2015-03-18 | Hudson Bay Capital Management LP | 10% Owner | — | I | Warrant (right to buy) | 62,500 | 41.60 | 2.60M | 0 | — | ↗ |
| 2015-01-16 | SCHWARTZ MARK W. | Director / Officer | A-Award | A | Stock Option (right to buy) | 550,000 | 1.75 | 962.5K | 550,000 | — | ↗ |
| 2015-01-16 | Kivinski Margaret | Officer | A-Award | A | Stock Option (right to buy) | 50,000 | 1.75 | 87.5K | 50,000 | — | ↗ |
| 2015-01-16 | Dunlap Ryan | Officer | A-Award | A | Stock Option (right to buy) | 125,000 | 1.75 | 218.8K | 125,000 | — | ↗ |
| 2014-12-31 | SCHWARTZ MARK W. | Director / Officer | J-Other | A | Common Stock | 3,846 | 1.28 | 4.9K | 415,972 | — | ↗ |
| 2014-12-31 | Hillsberg Sanford | Director | — | I | Common Stock | 0 | 0.00 | — | 85,447 | — | ↗ |
| 2014-12-31 | Dunlap Ryan | Officer | J-Other | A | Common Stock | 3,846 | 1.28 | 4.9K | 11,650 | — | ↗ |
| 2014-09-16 | SCHWARTZ MARK W. | Director / Officer | A-Award | A | Stock Option (right to buy) | 200,000 | 2.23 | 446.0K | 200,000 | — | ↗ |
| 2014-07-28 | Kivinski Margaret | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2014-06-30 | SCHWARTZ MARK W. | Officer | J-Other | A | Common Stock | 2,461 | 2.60 | 6.4K | 412,126 | — | ↗ |
| 2014-06-30 | HAMILTON BRIAN L | Officer | J-Other | A | Common Stock | 2,461 | 2.60 | 6.4K | 2,461 | — | ↗ |
| 2014-06-30 | Dunlap Ryan | Officer | J-Other | A | Common Stock | 2,461 | 2.60 | 6.4K | 7,804 | — | ↗ |
| 2014-06-30 | Ahn Mark J | Director / Officer | J-Other | A | Common Stock | 2,461 | 2.60 | 6.4K | 116,225 | — | ↗ |
| 2014-04-18 | Einhorn Irving M. | Director | A-Award | A | Stock Option (right to buy) | 100,000 | 1.80 | 180.0K | 100,000 | — | ↗ |
| 2014-03-14 | Einhorn Irving M. | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2014-02-12 | Chin Richard | Director | M-Exempt | A | Common Stock | 37,500 | 1.71 | 64.1K | 187,500 | — | ↗ |
| 2014-02-07 | Nisi Rudolph | Director | P-Purchase | A | Common Stock | 20,000 | 4.94 | 98.7K | 23,500 | — | ↗ |
| 2014-02-03 | GALLIKER STEPHEN S | Director | M-Exempt | D | Stock Option (right to buy) | 50,000 | 0.85 | 42.5K | 0 | — | ↗ |
| 2014-01-30 | SCHWARTZ MARK W. | Officer | S-Sale | D | Common Stock | 100,000 | 5.57 | 556.5K | 409,665 | — | ↗ |
| 2014-01-30 | Hillsberg Sanford | Director | H-ExpireLong | D | Stock Option (right to buy) | 50,000 | 1.71 | 85.5K | 0 | — | ↗ |
Executive team
Top executives
Shares Outstanding
142.44M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Angelos M. Stergiou, M.D., Sc.D. h.c. President and Chief Executive Officer | 676.0K | — | 477.1K | 327.7K | 390.4K | 5.00 | 1.88M | 42.86% | ↗ |
| 2 | 2025 | Dragan Cicic, M. D. Senior Vice President, Chief Development Officer | 451.2K | — | 185.1K | 144.0K | 193.1K | 6.00 | 991.8K | 33.18% | ↗ |
| 3 | 2025 | John T. Burns Senior Vice President, Chief Financial Officer | 429.6K | — | 185.1K | 144.0K | 185.6K | 6.00 | 959.7K | 34.29% | ↗ |
| 4 | 2024 | Angelos M. Stergiou, M.D., Sc.D. h.c. President and Chief Executive Officer | 650.0K | — | 82.6K | 112.8K | 339.6K | 5.00 | 1.19M | 16.42% | ↗ |
| 5 | 2024 | Dragan Cicic, M. D. Senior Vice President, Chief Development Officer | 427.7K | 50.0K | 23.4K | 30.7K | 164.2K | 7.00 | 713.5K | 7.58% | ↗ |
| 6 | 2024 | John T. Burns Senior Vice President, Chief Financial Officer | 401.5K | 50.0K | 24.4K | 35.5K | 154.2K | 7.00 | 680.8K | 8.80% | ↗ |
| 7 | 2023 | Angelos M. Stergiou, M.D., Sc.D. h.c. President and Chief Executive Officer | 625.0K | — | 193.7K | 654.7K | 275.0K | 4.2K | 1.75M | 48.41% | ↗ |
| 8 | 2023 | Barbara Wood, Esq. Former Executive Vice President, General Counsel and Corporate Secretary | 442.0K | — | 66.8K | 240.8K | 146.7K | 7.00 | 913.9K | 33.66% | ↗ |
| 9 | 2023 | John T. Burns Senior Vice President, Chief Financial Officer | 365.0K | — | 66.8K | 225.8K | 125.6K | 14.6K | 797.7K | 36.67% | ↗ |
| 10 | 2023 | Dragan Cicic, M. D. Senior Vice President, Chief Development Officer | 403.5K | — | 53.4K | 165.6K | 140.4K | 15.6K | 778.5K | 28.13% | ↗ |
| 11 | 2022 | Angelos M. Stergiou, M.D., Sc.D. h.c. President and Chief Executive Officer | 593.5K | — | 235.0K | 795.3K | 326.4K | 5.00 | 1.95M | 52.77% | ↗ |
| 12 | 2022 | Barbara Wood, Esq. Former Executive Vice President, General Counsel and Corporate Secretary | 425.0K | 20.0K | 69.4K | 235.0K | 173.4K | 8.00 | 937.1K | 32.48% | ↗ |
| 13 | 2022 | John T. Burns Senior Vice President, Chief Financial Officer | 310.0K | — | 52.3K | 173.5K | 111.8K | 8.00 | 659.8K | 34.22% | ↗ |
| 14 | 2019 | Angelos M. Stergiou, M.D., Sc.D. h.c. President and Chief Executive Officer | 629.6K | 223.1K | — | 464.1K | — | 109.7K | 1.43M | 32.53% | ↗ |
| 15 | 2019 | Barbara A. Wood Executive Vice President, General Counsel and Corporate Secretary | 376.0K | 135.4K | — | 180.2K | — | 14.1K | 705.7K | 25.53% | ↗ |
| 16 | 2019 | Nicholas J. Sarlis, M.D., Ph.D., FACP Former Executive Vice President and Chief Medical Officer | 142.5K | 47.8K | — | 54.6K | — | 200.7K | 445.6K | 12.25% | ↗ |
| 17 | 2019 | John T. Burns Vice President, Finance and Corporate Controller | 255.0K | 70.8K | — | 98.3K | — | 12.7K | 436.7K | 22.50% | ↗ |
| 18 | 2018 | Angelos M. Stergiou, M.D., Sc.D. h.c. President and Chief Executive Officer | 549.0K | 141.3K | — | 343.6K | — | 206.5K | 1.24M | 27.70% | ↗ |
| 19 | 2018 | Nicholas J. Sarlis, M.D., Ph.D., FACP Executive Vice President and Chief Medical Officer | 373.7K | 106.4K | — | 253.2K | — | 50.0K | 783.3K | 32.32% | ↗ |
| 20 | 2018 | Nicholas J. Sarlis, M.D., Ph.D., FACP Former Executive Vice President and Chief Medical Officer | 373.7K | 106.4K | — | 253.2K | — | 50.0K | 783.3K | 32.32% | ↗ |
| 21 | 2018 | Barbara A. Wood Executive Vice President, General Counsel and Corporate Secretary | 294.2K | 133.1K | — | 185.8K | — | 17.5K | 630.7K | 29.46% | ↗ |
| 22 | 2018 | John T. Burns Vice President, Finance and Corporate Controller | 235.0K | 59.9K | — | 72.3K | — | 26.1K | 393.3K | 18.39% | ↗ |
| 23 | 2017 | Angelos M. Stergiou, M.D., Sc.D., h.c. President and Chief Executive Officer | 400.0K | 186.7K | — | — | — | 142.0K | 728.7K | 0.00% | ↗ |
| 24 | 2017 | Angelos M. Stergiou, M.D., Sc.D. h.c. President and Chief Executive Officer | 400.0K | 186.7K | — | — | — | 142.0K | 728.7K | 0.00% | ↗ |
| 25 | 2017 | Nicholas J. Sarlis, M.D., Ph.D., FACP Executive Vice President and Chief Medical Officer | 438.9K | 161.0K | — | — | — | 17.0K | 616.9K | 0.00% | ↗ |
| 26 | 2017 | Nicholas J. Sarlis, M.D., Ph.D., FACP Chief Medical Officer and Senior Vice President | 438.9K | 161.0K | — | — | — | 17.0K | 616.9K | 0.00% | ↗ |
| 27 | 2017 | Gregory M. Torre, Ph.D., J.D Former Chief Regulatory Officer and Senior Vice President, Technical Operations | 285.0K | 115.0K | — | — | — | 9.9K | 409.9K | 0.00% | ↗ |
| 28 | 2017 | Aleksey Krylov, CFA Interim Chief Financial Officer | 51.2K | — | — | — | — | 225.00 | 51.5K | 0.00% | ↗ |
| 29 | 2016 | Angelos M. Stergiou, M.D., Sc.D., h.c. President and Chief Executive Officer | 133.3K | — | 1.93M | — | — | 117.7K | 2.18M | 88.47% | ↗ |
| 30 | 2016 | Gregory M. Torre, Ph.D., J.D Former Chief Regulatory Officer and Senior Vice President, Technical Operations | 369.0K | 50.0K | — | 346.8K | — | 3.3K | 822.4K | 42.17% | ↗ |
| 31 | 2016 | Bijan Nejadnik Chief Medical Officer | 400.0K | 140.0K | — | 45.0K | — | 2.6K | 587.6K | 7.66% | ↗ |
| 32 | 2016 | Mark W. Schwartz, Ph.D. Former President & Chief Executive Officer | 569.3K | — | — | — | — | 2.6K | 571.8K | 0.00% | ↗ |
| 33 | 2016 | Thomas Knapp Interim General Counsel | 334.8K | 90.4K | — | 31.3K | — | 2.6K | 459.0K | 6.82% | ↗ |
| 34 | 2016 | Nicholas J. Sarlis, M.D., Ph.D., FACP Chief Medical Officer and Senior Vice President | 99.5K | — | — | 276.5K | — | 5.0K | 376.0K | 73.53% | ↗ |
| 35 | 2016 | Stephen Ghiglieri Interim Chief Executive Officer and Chief Financial Officer | 61.7K | 66.7K | — | 191.5K | — | 60.0K | 319.9K | 59.88% | ↗ |
| 36 | 2016 | John Burns Vice President, Finance and Corporate Controller | 180.3K | 53.8K | — | 64.6K | — | 1.5K | 300.2K | 21.52% | ↗ |
| 37 | 2015 | Mark W. Schwartz, Ph.D. Former President & Chief Executive Officer | 544.2K | 330.0K | — | 1.88M | — | 1.4K | 2.76M | 68.26% | ↗ |
| 38 | 2015 | Mark W. Schwartz, Ph.D. President & Chief Executive Officer | 544.2K | 330.0K | — | 1.88M | — | 1.4K | 2.76M | 68.26% | ↗ |
| 39 | 2015 | Ryan M. Dunlap Vice President, Chief Financial Officer | 280.0K | 42.1K | — | 145.3K | — | 141.6K | 609.0K | 23.86% | ↗ |
| 40 | 2015 | Bijan Nejadnik Chief Medical Officer | 66.7K | 100.0K | — | 442.0K | — | 239.00 | 608.9K | 72.59% | ↗ |
| 41 | 2015 | Bijan Nejadnik , M.D. Chief Medical Officer | 66.7K | 100.0K | — | 442.0K | — | 239.00 | 608.9K | 72.59% | ↗ |
| 42 | 2015 | Thomas Knapp Interim General Counsel | 163.5K | 48.8K | — | 194.9K | — | 1.1K | 408.3K | 47.73% | ↗ |
| 43 | 2015 | Thomas Knapp, J.D. Interim General Counsel | 163.5K | 48.8K | — | 194.9K | — | 1.1K | 408.3K | 47.73% | ↗ |
| 44 | 2015 | Margaret Kivinski Former General Counsel | 160.4K | — | — | 58.1K | — | 100.7K | 319.2K | 18.21% | ↗ |
| 45 | 2014 | Mark W. Schwartz, Ph.D. Former President & Chief Executive Officer | 419.1K | 288.0K | — | 306.2K | — | 1.5K | 1.01M | 30.17% | ↗ |
| 46 | 2014 | Mark W. Schwartz, Ph.D. President & Chief Executive Officer | 419.1K | 288.0K | — | 306.2K | — | 1.5K | 1.01M | 30.17% | ↗ |
| 47 | 2014 | Margaret Kivinski Former General Counsel | 130.5K | 15.0K | — | 407.6K | — | 52.4K | 605.5K | 67.32% | ↗ |
| 48 | 2014 | Ryan M. Dunlap Vice President, Chief Financial Officer | 258.1K | 41.3K | — | — | — | 1.1K | 300.5K | 0.00% | ↗ |
| 49 | 2013 | Mark J. Ahn, Ph.D. President and Chief Executive Officer | 487.0K | 250.0K | — | — | — | 693.00 | 3.10M | 0.00% | ↗ |
| 50 | 2013 | Mark W. Schwartz, Ph.D. President & Chief Executive Officer | 365.0K | 125.0K | — | 1.09M | — | 693.00 | 1.58M | 69.03% | ↗ |
| 51 | 2013 | Mark W. Schwartz, Ph.D. Executive Vice President and Chief Operating Officer | 365.0K | 125.0K | — | — | — | 693.00 | 1.58M | 0.00% | ↗ |
| 52 | 2013 | Brian Hamilton, M.D., Ph.D. Executive Vice President and Chief Medical Officer | 57.3K | 70.0K | — | — | — | 43.00 | 930.3K | 0.00% | ↗ |
| 53 | 2013 | Rosemary Mazanet, M.D., Ph.D. Former Executive Vice President and Chief Medical Officer | 390.0K | — | — | — | — | 693.00 | 913.8K | 0.00% | ↗ |
| 54 | 2013 | Ryan M. Dunlap Vice President, Chief Financial Officer | 195.0K | 41.0K | — | — | — | 366.00 | 684.4K | 0.00% | ↗ |
| 55 | 2013 | Ryan M. Dunlap Vice President, Chief Financial Officer | 195.0K | 41.0K | — | 448.0K | — | 366.00 | 684.4K | 65.46% | ↗ |
| 56 | 2012 | Mark J. Ahn, Ph.D. President and Chief Executive Officer | 447.9K | 217.0K | — | — | — | 693.00 | 1.01M | 0.00% | ↗ |
| 57 | 2012 | Rosemary Mazanet, M.D., Ph.D. Former Executive Vice President and Chief Medical Officer | 274.9K | 185.0K | — | — | — | 317.00 | 729.4K | 0.00% | ↗ |
| 58 | 2012 | Mark W. Schwartz, Ph.D. Executive Vice President and Chief Operating Officer | 350.0K | 105.0K | — | — | — | 693.00 | 551.6K | 0.00% | ↗ |
| 59 | 2012 | Ryan M. Dunlap Vice President, Chief Financial Officer | 81.0K | 60.0K | — | — | — | 144.00 | 233.1K | 0.00% | ↗ |
| 60 | 2012 | Brian Hamilton, M.D., Ph.D. Executive Vice President and Chief Medical Officer | — | — | — | — | — | — | — | — | ↗ |
| 61 | 2011 | Mark J. Ahn, Ph.D. President and Chief Executive Officer | 320.7K | 257.7K | — | — | — | 225.00 | 1.25M | 0.00% | ↗ |
| 62 | 2011 | Mark W. Schwartz, Ph.D. Executive Vice President and Chief Operating Officer | 235.7K | 108.2K | — | — | — | 213.00 | 568.3K | 0.00% | ↗ |
| 63 | 2011 | Ryan M. Dunlap Vice President, Chief Financial Officer | — | — | — | — | — | — | — | — | ↗ |
| 64 | 2011 | Rosemary Mazanet, M.D., Ph.D. Former Executive Vice President and Chief Medical Officer | — | — | — | — | — | — | — | — | ↗ |
| 65 | 2011 | Brian Hamilton, M.D., Ph.D. Executive Vice President and Chief Medical Officer | — | — | — | — | — | — | — | — | ↗ |
| 66 | 2007 | James Warren Former Chief Financial Officer and Secretary Pamela Pavco, Ph.D. Vice President of Pharmaceutical Development Dmitry Samarsky, Ph.D. Vice President of Technology and Business Development | 216.3K | 87.5K | — | — | — | 33.3K | 573.6K | 0.00% | ↗ |
| 67 | 2006 | Tod Woolf, Ph.D. President and Chief Executive Officer Stephen J. DiPalma Chief Financial Officer and Secretary | — | — | — | — | — | 115.8K | 115.8K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Angelos Stergiou | Founder, President, Chief Executive Officer & Director | 1M | — |
| Dragan Cicic | Senior Vice President & Chief Development Officer | 662.7K | — |
| John Thomas Burns | Senior Vice President & Chief Financial Officer | 630.6K | male |
| Andrew Elnatan | Senior Vice President of Regulatory Affairs, CMC & Quality | — | male |
| Stacy Yeung | VP, General Counsel & Corporate Secretary | — | female |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SLS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
